Many signalling pathways have been identified to regulate liver growth during organ development and tumour formation. It is unclear, however, how these signals provide energy and cellular building blocks to enable rapid cell division and organ growth. The Hippo signalling pathway has emerged as an evolutionarily conserved master regulator of organ size and tissue growth 1 . The Hippo kinase cascade regulates the transcriptional co-activator Yap that binds the Tead family of transcription factors to enhance cell proliferation, inhibit cell death and alter cell fate 2 . The Hippo pathway is frequently perturbed in human cancers 3 , and many oncogenic pathways feed into the Hippo pathway and sustain growth in a Yap-dependent manner. The molecular mechanisms by which Yap target genes contribute to rapid cell proliferation to increase organ size remain elusive.
Altered cellular metabolism is a hallmark of cancer cells 4 . Several studies have focused attention on the alternative means by which cancer cells produce ATP, including aerobic glycolysis 5 or the anaplerotic use of alternative fuel sources such as glutamine 6 . While the mTOR pathway can enhance de novo synthesis of building blocks and macromolecules required for cell growth 7 , it remains unknown whether the Hippo pathway can similarly reprogram cellular metabolism to match the demands for rapid tissue growth.
Here, we investigate zebrafish with hepatocyte-specific transgenic expression of activated yap1 S87A that develop hepatomegaly as larvae and are prone to liver tumour formation as adults. Transcriptomic and metabolomic analyses reveal that Yap1 induces glutamine synthetase (glul) to elevate glutamine levels and stimulate de novo nucleotide biosynthesis. Treatment studies in larval and adult zebrafish demonstrate that inhibition of Glul or nucleotide biosynthesis diminishes Yap-induced liver growth. YAP-dependent regulation of GLUL is required for growth of human liver cancer cells. Our studies define a role for Yap in reprogramming cellular metabolism to fulfil the anabolic requirements for tissue growth and illustrate the therapeutic potential of targeting Yap-driven metabolic alterations.
RESULTS
Hepatocyte-specific overexpression of activated Yap causes hepatomegaly and accelerates DMBA-induced liver tumour formation To investigate the impact of Yap activation on liver growth in zebrafish larvae, transgenic zebrafish (Tg(-2.8fabp10a:yap1-1β S87A ), referred to as lf:Yap, were generated with hepatocyte-specific expression of constitutively active Yap1, homologous to human YAP1(S127A) (Supplementary Fig. 1A ). Liver development was visualized using the Tg (-2.8fabp10a:eGFP) (lf:GFP) hepatocyte reporter line 8 . At 5 days post fertilization (dpf), lf:Yap fish exhibit a 36% increase in liver area (Fig. 1a,b ) compared with wild-type (WT) siblings. Single-plane illumination confocal microscopy confirmed liver volume enlargement and preservation of gross architectural features of the bilobed larval liver in lf:Yap transgenics (Fig. 1c,d ). Increased liver size was accompanied by hepatocyte hyperproliferation without significantly enlarged cell size, as determined by histological and fluorescence-activated cell sorting analyses ( Supplementary  Fig. 1B ,C). Enhanced liver size in lf:Yap fish persisted into adulthood at 16 weeks post fertilization (wpf), as quantified by fluorescent liver area ( Fig. 1e and Supplementary Fig. 1D ) and a twofold increase in liver-to-body weight ratio (Fig. 1f ). Histological analysis of lf:Yap fish revealed liver hyperplasia with increased cellularity, cell proliferation, decreased glycogen, and focally elevated bile duct density ( Supplementary Fig. 1E ). These data demonstrate that Yap induces hepatomegaly and promotes liver hyperplasia in zebrafish.
To examine whether Yap predisposes to neoplasia, juvenile WT and lf:Yap transgenics were exposed to the carcinogen dimethylbenzanthracene (DMBA) 9 ( Fig. 1g) . lf:Yap transgenics formed liver tumours earlier and with greater frequency than WT siblings (Fig. 1h) , with liver masses occupying the entire abdominal cavity (Fig. 1i) . Tumour differentiation subtypes ranged from hepatocellular carcinoma, with occasional foci of sarcomatoid cytology and/or peliosis/spongiosishepatis-like change, to cholangiocarcinoma ( Fig. 1j and Supplementary Fig. 1F,G) . Ascites was noted in 30% (7/23) of lf:Yap transgenics and 0% (0/5) of WT. These data demonstrate that Yap exerts oncogenic activity, enhancing chemically induced hepatocarcinogenesis.
Yap alters expression of metabolism-related genes and enhances glul expression
To identify signals responsible for Yap-driven liver hyperplasia, we performed transcriptional profiling in WT and lf:Yap adult livers, revealing a large number of differentially expressed genes (Fig. 2a) . Gene set enrichment analysis was consistent with a mammalian Hippo signature (Supplementary Fig. 2A ) 10 . Intriguingly, gene ontology analysis indicated a relationship to metabolism in 34% of annotated categories (Fig. 2b) , and ∼60% of the top 20 biological processes upregulated by Yap were related to metabolism ( Supplementary  Fig. 2B ). Amongst the most differentially upregulated genes were the established Yap targets amotl2, ctgf and cyr61, as well as zebrafish orthologues of glutamine synthetase (GLUL), glula and glulb (Fig. 2c) . Quantitative PCR (qPCR) verified induction of ctgf, cyr61, amotl2, glula and glulb in lf:Yap livers (Fig. 2d,e) . GLUL plays a central role in nitrogen assimilation in the liver by catalysing the formation of glutamine from glutamate and ammonia. While GLUL expression can be regulated by Wnt activity 11 , the Wnt targets cyclinD1, axin2 or cd44 were not induced in lf:Yap transgenics ( Supplementary Fig. 2C,D) . yap expression, but not taz, was dramatically increased in lf:Yap livers ( Supplementary Fig. 2E ). Collectively, these results suggest that Yap regulates glutamine metabolism.
Yap transcriptionally upregulates GLUL in an evolutionarily conserved fashion
To determine whether Yap directly influences GLUL expression, chromatin immunoprecipitation (ChIP) on isolated adult zebrafish liver lysates was performed. Yap1 occupancy was enriched at the transcriptional start site of the glula promoter as avidly as at ctgf (Fig. 3a and Supplementary Fig. 3A ). Mammalian conservation of Yap-dependent GLUL regulation was demonstrated in, a luciferase reporter assay in HEK293T cells: constitutively active YAP1(S127A) enhanced GLUL expression, whereas mutant YAP1 lacking the ability to co-activate TEAD (YAP1(S94A)) did not equally induce GLUL (Fig. 3b) . Promoter fragmentation analysis found several regions within the promoter to contribute to the total YAP1-induced activity increase, suggesting several binding sites ( Supplementary Fig. 3B ). ChIP analysis for YAP1 in HepG2 cells revealed occupation of the GLUL promoter in the region associated with luciferase activation (Supplementary Fig. 3C ). To further demonstrate the dependency of GLUL expression on Yap activity, genetic and chemical strategies were utilized: short hairpin RNA (shRNA)-mediated knockdown of YAP1 and chemical inhibition with verteporfin 12 in Hep3B and HepG2 liver cancer cell lines reduced GLUL (Fig. 3c,d) . Together, these studies demonstrate that direct regulation of GLUL expression by YAP1 is evolutionarily conserved in humans.
Yap reprograms nitrogen metabolism by enhancing GLUL-dependent anabolic assimilation of ammonia for de novo nucleotide biosynthesis
To examine the effect of Yap activation on cellular metabolism, adult WT and lf:Yap livers were subjected to polar steady-state metabolomics analysis by liquid chromatography-based tandem mass spectrometry (LC-MS/MS) 13 , determining >250 metabolite profiles. Hierarchical clustering based on metabolite abundance revealed significant changes in steady-state levels of many metabolites (Fig. 4a , n = 5, P < 0.05), including enrichment of metabolites associated with protein biosynthesis, purine and pyrimidine metabolism (Fig. 4b) . Significantly, lf:Yap livers contained twice the amount of glutamine as WT (Fig. 4c) . Further, GLUL enzyme activity in lf:Yap liver homogenate was increased tenfold compared with WTs (Fig. 4d) , and immunohistochemistry demonstrated uniform overexpression of Glul in lf:Yap hepatocytes and heterogeneous expression in Yap-driven liver tumours ( Supplementary Fig. 4A ). Ammonia excretion rates were decreased when assessed in vivo in lf:Yap fish, consistent with enhanced nitrogen retention due to the catalytic role of GLUL in the formation of glutamine from glutamate and ammonia ( Supplementary  Fig. 4B ). Similarly, metabolomics analysis detected decreased urea levels in lf:Yap livers ( Supplementary Fig. 4C ).
To more precisely determine the GLUL-dependent fate of ammonia, liver lysates were incubated with 15 N-labelled NH 4 Cl and ATP with or without the GLUL inhibitor methionine sulfoximine (MSO; Fig. 4e ). Glutamine is essential for de novo nucleotide Supplementary Table 4 ). * P < 0.05, * * P < 0.01, * * * P < 0.001, two-sided Student's t-test; values represent the mean ± s.e.m. (e) qPCR validation of Glul induction in dissected WT and lf:Yap transgenic livers. n = 3 WT and lf:Yap adult livers (see Supplementary Table 4 ). * * P < 0.01, two-sided Student's t-test; values represent the mean ± s.e.m.
by LC-MS/MS using selected reaction monitoring for potential 15 N isotopologues and revealed that 15 N-labelled isotopologues of guanosine and cytosine were increased in lf:Yap liver lysates (Fig. 4f,g and Supplementary Fig. 4D ,E). This response was inhibited by MSO. In contrast, little change was observed in the relative isotopic enrichment of 15 N into glutamine or histidine ( Supplementary  Fig. 4F,G ). These results demonstrate that Yap reprograms nitrogen metabolism by activating GLUL and promoting the incorporation of ammonia-bound nitrogen to form glutamine as a precursor for nucleotide biosynthesis.
GLUL activity and nucleotide biosynthesis contribute to Yap-induced hepatomegaly and the growth of liver cancer cells
Given the dramatic impact of Yap on GLUL expression and nitrogen metabolism the requirement of GLUL in mediating Yap-induced rapid liver growth was examined utilizing morpholino (MO)-mediated knockdown of glula and glulb ( Supplementary Fig. 5A ). Yap-induced hepatomegaly at 5 dpf was attenuated in glula/glulb morphants (Fig. 5a,b) . To demonstrate potential therapeutic implications, larvae were exposed to MSO from 3 to 5 dpf, which effectively inhibited GLUL activity ( Supplementary Fig. 5B ) and significantly inhibited Yap-driven hepatomegaly (Fig. 5c ). Importantly, both glula/glulb knockdown and MSO treatment had no effect on liver size or morphology in WT larvae (Fig. 5a-c) . Given the increased relative isotopic enrichment of 15 N in nucleotide intermediates in lf:Yap transgenics, consistent with stimulation of nucleotide biosynthesis, we investigated whether inhibitors of purine or pyrimidine biosynthesis impacted Yap-driven hepatomegaly: the purine analogue mycophenolic acid (MPA), which inhibits inosine monophosphate dehydrogenase (IMPDH), significantly suppressed Yap-driven hepatomegaly (Fig. 5d) . Furthermore, the combined treatment of MSO and MPA had an additive effect on liver size (Fig. 5d) . Similarly, exposure to the pyrimidine analogue 5-fluorouracil (5FU), which inhibits thymidylate synthase, also suppressed Yap-driven hepatomegaly, but showed no synergy with MSO ( Fig. 5e ). Interestingly, in each case there was no significant impact on WT liver growth (Fig. 5d,e) . To examine the conserved nature of the Yap-GLUL axis, Hep3B and HepG2 human liver cancer cells were cultured in the presence or absence of glutamine, MSO or verteporfin. Verteporfin suppressed proliferation of Hep3B cells in full media and caused cytostasis in glutamine-deficient media ( Fig. 5f , n = 3). Interestingly, MSO exposure had no effect on Hep3B cell proliferation in full media; however, in glutamine-deprived conditions, Hep3B cell number decreased significantly (Fig. 5f ). Similar effects of verteporfin and MSO were observed in HepG2 cells cultured in glutamine-deprived conditions ( Supplementary Fig. 5C ). Together, these studies suggest that GLUL and nucleotide biosynthesis are conditionally required for rapid cell proliferation in the context of Yap-driven hepatomegaly and liver cancer cell growth. 
mTOR pathway is not deregulated by Yap expression or GLUL inhibition, but is required for Yap-induced hepatomegaly
Given the important role of mTOR in stimulating nucleotide biosynthesis to fuel cell growth 7 , we examined levels of phospho-Akt (p-Akt, Ser473), an mTORC2 target, as well as phospho-S6 (p-S6), a substrate of S6K: no significant differences were seen in WT and lf:Yap liver homogenates and histological sections ( Fig. 6a and Supplementary Fig. 6A ). Importantly, the mTOR inhibitor rapamycin completely suppressed p-Akt and p-S6 levels; MSO exposure led to a subtle increase in p-Akt and p-S6 levels (Fig. 6a) . mTOR pathway activation typically leads to increased cell size 7 . Hepatocyte size was examined by liver cell counts, liver area and cellularity in liver sections from WT and lf:Yap larvae and was unaffected by Yap expression ( Supplementary Fig. 6B-D) . To determine whether the mTOR pathway was required for Yap-driven liver growth WT and lf:Yap larvae were exposed to rapamycin with or without MSO, which suppressed Yap-driven liver growth, but did not synergize with MSO (Fig. 6b) . Together, these experiments demonstrate that Yap does not significantly stimulate the mTOR pathway; however, intact mTOR signalling is necessary for Yap-driven liver growth. Furthermore, the mechanism by which MSO suppresses liver growth is independent of mTOR pathway.
Yap reprograms the relative isotopic enrichment of nutritional nitrogen into nucleotide biosynthesis in a GLUL-dependent manner to support liver growth
The steady-state metabolomics data indicated that Yap alters nitrogen metabolism, but did not define how nitrogen is utilized in vivo to accelerate tissue growth. To examine the fate of increased glutamine content in lf:Yap transgenics we developed a feeding methodology for stable isotope labelling in fish to assess relative isotopic enrichment in vivo:
15 N-labelled Spirulina gel pellets were prepared to provide a defined and consistent amount of 15 N-labelled nutrition. Individual WT and lf:Yap fish were fed twice weekly and maintained in the presence or absence of MSO (twice weekly for 48 h) for 4 weeks (Fig. 7a) . Subsequently, liver DNA was extracted and hydrolysed into nucleotides for analysis ( Supplementary Fig. 7A ) to focus exclusively on the fraction of nitrogen incorporated into nucleotides to synthesize DNA and not on other nucleic acid-containing macromolecules, such as RNA. The DNA of lf:Yap transgenic livers contained significantly higher amounts of 15 N-labelled nucleotides than WT, with three times as much deoxyinosine, twice as much deoxyguanosine and 65% more deoxyadenosine (Fig. 7b) . Yap-induced increase in nucleotide biosynthesis was mitigated to baseline levels by MSO. The relative Table 4 ). * P < 0.05, * * * P < 0.001, * * * * P < 0.0001, two-sided Student's t-test; values represent the mean ± s.e.m. (e) Quantitative analysis of the effect of 5FU treatment from 3 to 5 dpf on liver size as determined by fluorescence microscopy. n = 101, 185, 56, 50, 103, 210, 105 and 92 WT, WT+MSO, WT+5FU, WT+MSO+5FU, lf:Yap, lf:Yap+MSO, lf:Yap+5FU and lf:Yap+MSO+5FU larvae, respectively (see Supplementary Table 4 ). * * P < 0.01, * * * * P < 0.0001, two-sided Student's t-test; values represent the mean ± s.e.m. (f) Proliferation of Hep3B liver cancer cells over 4 days in the presence or absence of glutamine (Q), MSO or verteporfin (VP). n = 3 biologically independent replicates (see Supplementary Table 4) . Values represent the mean ± s.e.m.
isotopic enrichment reveals that Yap reprograms nitrogen metabolism by stimulating anabolic incorporation of glutamine into nucleotides in a GLUL-dependent manner.
To evaluate functional consequences and potential therapeutic impact of GLUL inhibition on adult liver hyperplasia, fish were exposed to MSO twice weekly over a 4-week period to efficiently inhibit GLUL activity in vivo (Fig. 7d) . Short-term exposure to MSO (for 48 h) suppressed hepatocyte proliferation, as examined by quantification of PCNA + nuclei in histological sections (Fig. 7d,e) . Importantly, MSO exposure did not cause cell death as determined by TUNEL staining (Supplementary Fig. 7B ). Prolonged MSO treatment significantly reduced hepatomegaly in lf:Yap transgenics (Fig. 7f) . MSO exposure had no effect on overall morphology and liver size in WT, suggesting that GLUL is conditionally required for accelerated hepatic growth following induction of Yap1. These data show that Yap elevates GLUL activity and augments glutamine production, which is essential for nucleotide biosynthesis and DNA assembly during rapid liver growth.
DISCUSSION
In this study, transgenic zebrafish expressing activated Yap1 in differentiated hepatocytes demonstrated rapid onset of Yap-dependent larval hepatomegaly that persists into adulthood, along with increased susceptibility to carcinogen-induced hepatocarcinogenesis. Combined transcriptomic and metabolomic analyses revealed that Yap reprograms nitrogen metabolism by inducing GLUL and elevating steady-state levels of glutamine available for biosynthetic growth. The transcriptional regulation of GLUL by YAP and its impact on growth is evolutionarily conserved. Therapeutic prevention studies with the GLUL inhibitor MSO determined that elevated GLUL activity Table 4 ). * * * P < 0.001, * * * * P < 0.0001, two-sided Student's t-test; values represent the mean ± s.e.m. NS, not significant. and nucleotide biosynthesis contribute to Yap-driven hepatomegaly. Collectively, our data establish that Yap reprograms glutamine metabolism to provide essential cellular building blocks for hepatic growth. Given that the Hippo pathway is frequently deregulated in cancer, targeting the metabolic alterations driven by Yap activation is a highly attractive and rational therapeutic approach.
Murine studies demonstrated that Yap alters liver cell fate, induces hepatomegaly and promotes tumorigenesis [14] [15] [16] . The downstream mechanisms responsible for Yap-driven organ growth, however, have not been fully elucidated. Using zebrafish and unbiased surveys of gene expression and metabolic changes, we identified that Yap reprograms glutamine metabolism through GLUL induction. This results in enhanced de novo nucleotide biosynthesis to meet the anabolic demands of rapid cell proliferation. GLUL is often overexpressed in human hepatoblastoma 17 , hepatocellular adenoma 18 and early stage hepatocellular carcinoma 19 . Consistent with these observations, Glul expression and activity are upregulated in Yap-expressing premalignant liver. Glul has been previously characterized as a Wnt target in perivenous hepatocytes 11 . In contrast, Yap is enriched in a subset of ductal cells during liver homeostasis 16 ; however, Yap levels are elevated in hepatocytes during liver tumorigenesis 20 . Previous ChIP-seq studies examining YAP and TEAD target genes in MCF7 and embryonic stem cells also showed that Yap binds to the GLUL promoter 21, 22 . The Hippo and Wnt pathways appear to have a complex relationship, acting synergistically 23, 24 and antagonistically 25, 26 in different contexts to regulate gene expression. Given the key role of GLUL in nitrogen metabolism, it is not surprising that Met 27 , Gata3 28 and Foxo 29 also regulate GLUL in other contexts. We speculate that GLUL overexpression provides tumour cells with a competitive advantage by fulfilling the biosynthetic demands for rapid cell proliferation.
One key feature of malignancy is altered cellular metabolism. Tumour cells exploit metabolic pathways to increase nutrient uptake and bioenergetic output. Aerobic glycolysis ('Warburg effect') and glutaminolysis (glutamine catabolism to generate TCA cycle intermediates) are among the best described metabolic changes in cancer 5, 6 . A less appreciated aspect of cancer cell metabolism is the need to rewire carbon and nitrogen flux to generate the building blocks required for the anabolic requirements of rapid cell growth 30 . Growing tissue needs lipids to generate membranes, amino acids for macromolecules and proteins, and nucleotides for DNA and RNA synthesis 31 . Recent studies examining the metabolic profiles of Kras-induced pancreatic cancer 32 and Myc-driven lymphomas 33 have identified a common theme in metabolic reprogramming, namely the production of precursors for nucleotide biosynthesis. Here, we discover that Yap reprograms glutamine metabolism to enhance nucleotide biosynthesis and fuel liver growth. Our findings support several recent reports that have elegantly shown that GLUL overexpression can promote cancer cell growth in glutamine-deprived conditions by enhancing nucleotide biosynthesis 34, 35 . Our studies are also consistent with recent insights showing that Ras-driven lung tumours are less dependent on glutamine catabolism (glutaminolysis) than cultured cells 36 . Collectively, these studies illustrate the importance of anabolic glutamine utilization for biosynthetic output and cancer cell growth.
Our in vivo relative isotopic enrichment studies enable tracking of nutritional nitrogen in a complex vertebrate organism like very few studies before 36, 37 . Although our studies focused attention on the anabolic utilization of glutamine for nucleotide biosynthesis, elevated glutamine could also contribute to other biosynthetic outputs including protein synthesis, transamination and the hexosamine biosynthesis pathway. Furthermore, we predict that Yap can alter expression of other metabolic enzymes to enhance utilization of nitrogen and carbon and remodel cellular metabolism. In our work, we highlight the therapeutic potential of targeting anabolic glutamine metabolism with MSO. There is a rich history of targeting the metabolic adaptations of cancer cells as a therapeutic strategy. Many of the first cancer drugs were antimetabolites targeting folate and nucleotide biosynthesis 5, 38 . Antifolates such as methotrexate Supplementary Table 4 ). * P < 0.05, * * P < 0.01, two-sided Student's t-test; values represent the mean ± s.e.m. (c) Glul activity in liver lysates extracted from WT and lf:Yap fish in the presence or absence of MSO. n = 12, 12, 18 and 10 biologically independent WT, WT+MSO, lf:Yap and lf:Yap+MSO adult liver lysates, respectively (see Supplementary Table 4 ). * P < 0.001, two-sided Student's t-test; values represent the mean ± s.e.m. and nucleoside analogues including 5FU, gemcitabine and cytarabine remain a linchpin of modern chemotherapy in many cancers. Indeed, we found that Yap-driven liver growth was sensitive to the nucleoside analogues MPA and 5FU. The ability to convert nutrients into biomass is an essential characteristic of tumours that may provide a therapeutic window for novel antimetabolite strategies.
Functional crosstalk between the mTOR and Hippo pathways during tissue growth is well described 39 . The mTOR pathway is essential in linking nutrient status with metabolic processes underlying anabolic cell growth 7 . Intracellular nutrients activate mTOR, altering metabolic flux to generate the lipids, protein and nucleic acids for cell proliferation. For example, the mTOR pathway phosphorylates and thereby activates CAD, which catalyses the first three steps of pyrimidine biosynthesis 40, 41 . mTOR also stimulates purine biosynthesis by inducing enzymes associated with the mitochondrial tetrahydrofolate cycle 42 . Similarly, lysophosphatidic acid, sphingosine 1-phosphate and the mevalonate pathway regulate Yap, thereby establishing Yap as a sensor of nutrient status [43] [44] [45] [46] . Serum starvation activates Amot130, which binds Yap and facilitates its degradation by recruiting the E3 ubiquitin ligase Aip4 47, 48 . In the context of liver growth, bile acids derived from mevalonate precursors activate Yap to promote carcinogenesis 49 . In addition to serum-borne lipids, glucose deprivation and bioenergetic stress inhibit Yap activation via AMPK and LATS1/2 [50] [51] [52] [53] . In turn, Yap directly induces the expression of the amino acid transporters SLC38A1 and SLC7A5, which are required for cancer cell growth as they stimulate amino acid uptake and activate mTORC1 54, 55 . In light of these studies and the insights provided by our work, we hypothesize that Yap functions to 'sense' the nutrient status of the environment and initiate an appropriate growth response. Given the striking similarities between the mTOR and Hippo pathways as networks that integrate metabolite availability to anabolic growth, it will be interesting to further define these links in the context of cancer.
In summary, our study provides compelling evidence that metabolic reprogramming contributes to the accelerated growth phenotype imbued by Yap activation. A greater understanding of the metabolic perturbations specific to malignant cells may provide new pharmacological approaches to combat cancer.
METHODS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of this paper. s705 , abbreviated lf:Yap, were generated using standard techniques 57 . These zebrafish express a constitutively active form of yap1-1β S87A , a gift from I. Scott (The Hospital for Sick Children, Canada), driven by the hepatocyte-specific promoter of fatty acid binding protein (fabp) 10a, otherwise known as liver specific fatty acid binding protein (lfabp or lf ) 56 . This line also contains the A-crystallin (cryaa)-driven selection marker Venus 58 , to produce green fluorescence in the lens of the eye. Adult zebrafish were used without sex bias (both males and females, in a gender-matched fashion), unless otherwise indicated. For the adult zebrafish studies, at least three individuals were used for all assays and the age of the individuals examined was 3 months old (unless otherwise stated in the text).
Chemical exposure. Zebrafish were exposed to methionine sulfoximine (MSO, 1 mM), mycophenolic acid (MPA, 10 µM), 5-fluorouracil (5FU, 10 µM) and rapamycin (0.5 µM) as described. Cultured cells were exposed to verteporfin (5 µM) and MSO 1 mM), as described. Where necessary chemicals were dissolved in dimethylsulfoxide. Chemicals were obtained from Sigma-Aldrich (USA).
Morpholino injection. Morpholinos (MO) (GeneTools USA) designed against exon2-intron2 splice sites of glula and glulb or mismatched controls glula-MM and glulb-MM (see Supplementary Table 1) were injected into Tg(-2.8fabp10a:eGFP) and Tg(-2.8fabp10a:eGFP); lf:Yap larvae at the one-cell stage.
Fluorescence determination of liver size. lf:GFP larvae were anaesthetized with 0.04 mg ml −1 tricaine methane sulfonate (MS-222) and imaged by fluorescence microscopy using a Zeiss Discovery V8/Axio Cam MRC. Lightsheet microscopy was performed using a Zeiss Lightsheet Z.1 at the Harvard Center for Biological Imaging (HCBI) core and analysed using FIJI (NIH) as previously described 59 .
Histology. Paraformaldehyde (PFA)-fixed fish larvae were paraffin-embedded, serially sectioned and stained with haematoxylin and eosin (H&E), periodic acidSchiff or Sirius Red stain using standard protocols 60 . Analysis of PCNA + nuclei and cellularity (cells per unit 2 ) was performed using FIJI (NIH) as previously described 59 .
Immunohistochemistry. Fixed tissue embedded in paraffin was serially sectioned before immunohistochemical analysis. Slides were deparaffinized and rehydrated before heat-induced antigen retrieval. Antigens were detected using primary antibodies (Supplementary Table 2 ) in conjunction with an HRP/DAB (ABC) detection kit (Abcam, ab64264) or fluorophore-conjugated secondary antibodies. TUNEL staining was performed according to the manufacturer's instructions (R&D Systems).
Fluorescence-activated cell sorting analysis. lf:GFP larvae were dissociated at 10 dpf by enzymatic disaggregation in TrypLE Express (Invitrogen) combined with manual disruption using a pestle. On addition of DMEM with 10% FCS, cells were strained through a 35 µm nylon mesh and analysed using a BD FACSAria II flow cytometer (BD Biosciences).
DMBA-induced carcinogenesis. WT and lf:Yap fry were exposed to 5 ppm DMBA for 24 h at 3, 4 and 5 weeks 9 . Fish were monitored closely for tumour development over the subsequent 6 months.
RNA transcriptomic analysis. RNA was extracted in Trizol (Life Technologies) from livers isolated from WT and lf:Yap adults and purified using the RNease Mini Kit (Qiagen), according to the manufacturer's instructions. RNA quality was checked by Agilent Bioanalyzer. Sequencing was performed after library construction on an Illumina HiSeq. polyA sequence data were aligned onto the ZV9 genomic assembly using STAR and differentially affected genes were identified using DeSeq 61 . Gene ontology and gene set enrichment analysis of biological processes was determined by GO Slim (Gene Ontology Consortium) and GAGE 62 .
qRT-PCR. RNA was isolated from pooled zebrafish larvae or isolated livers using Trizol. Following DNAse treatment, cDNA was synthesized using the SuperScript III First-Strand Synthesis kit (Life Technologies). qRT-PCR was performed on biological triplicates using an iCycler with iQ SYBR green (BioRad). Gene expression was analysed with ef1a as the reference gene (Supplementary Table 1 ). All of the primers used in this study were purchased from Integrated DNA Technologies.
ChIP analysis. Chromatin immunoprecipitation was performed as previously described 63 . Cells were crosslinked in 1% formaldehyde for 10 min at room temperature after which the reaction was stopped by addition of 0.125 M glycine.
Cells were lysed and harvested in ChIP buffer (100 mM Tris at pH 8.6, 0.3% SDS, 1.7% Triton X-100, and 5 mM EDTA) and the chromatin was disrupted by sonication using a Diagenode Bioruptor sonicator UCD-200 to obtain fragments of average 200-500 bp in size. Suitable amounts of chromatin were incubated with specific antibodies overnight (Supplementary Table 2 ). Immunoprecipitated complexes were recovered on Protein-A/G agarose beads (Pierce) and, after extensive washes, DNA was recovered by reverse crosslinking and purification using QIAquick PCR purification kit (QIAGEN).
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Determination of ammonia excretion rate. The rate of ammonia excretion was determined by placing individual fish into small water containers and monitoring ammonia build-up over time using methods previously established 68 and an ammonia detection kit (Biovision) according to the manufacturer's instructions.
Analysis of the relative isotopic enrichment in liver lysates following
15 NH 4 Cl exposure. Ammonia incorporation into nucleotide precursors was measured using adaptations to previously established methods 69 . Briefly, liver homogenates isolated from WT and lf:Yap adults were prepared in lysis buffer (100 mM NaCl, 25 mM imidazole, 25 mM HEPES, 1 mM MgCl 2 , 1 mM MnCl 2 , 0.1 mM KCl and 1% NP-40 pH 7.4 supplemented with Complete protease inhibitors (Roche)). Liver homogenates (90 µl) containing the same amount of protein were incubated in a reaction cocktail (10 µl) containing 10 mM 15 NH 4 Cl (Cambridge Isotopes Laboratories), 10 mM ATP and 10 mM sodium glutamate and incubated at 37 • C for 20 min before the reaction was quenched in 80% methanol (900 µl). Polar metabolites were enriched using the methodology previously described 13 and quantified using SRM on a 5500 QTRAP mass spectrometer using a protocol to detect 15 N-labelled isotopologues of nucleotide precursors (Supplementary Table 3 ).
15 N-Spirulina feeding protocol.
15 N-labelled Spirulina (98%) (Cambridge Isotopes Laboratories) gels containing 50 mg ml −1 15 N-labelled Spirulina, 5 mg ml −1 Gemma Micro 300 (Skretting) and 1% agar were aliquoted into 30 µl pellets. Individual WT and Tg(fabp10:yap1 S87A ) transgenic adults were given a 15 N-labelled Spirulina gel pellet twice a week over a 4-week period.
Analysis of the relative isotopic enrichment of
15 N in genomic DNA. Livers were isolated from adult WT and lf:Yap transgenic adults and genomic DNA was isolated using Quick-gDNA MiniPrep (Zymo Research) according to the manufacturer's instructions and re-purified by sodium acetate precipitation. DNA from 15 N-labelled Spirulina and unlabelled Spirulina was extracted as previously described 70 . Purified DNA was quantified with PicoGreen (Life Technologies), and 100 ng of DNA was treated with DNA Degradase Plus (Zymo Research) for 24 h. Completion of DNAse digestion was measured by PicoGreen quantification. Hydrolysed nucleotides were enriched using the methodology previously described 13 and quantified using SRM on a 5500 QTRAP mass spectrometer using a protocol to detect 15 N-labelled isotopologues of nucleotides (Supplementary Table 3 ).
Statistics and reproducibility. Sample sizes and reproducibility for each figure are denoted in the figure legends. Unless otherwise noted, all data including immunoblots and microscopy images are representative of at least three biologically independent experiments. For zebrafish experiments, no statistical method was used to predetermine sample size. Furthermore, the experiments were not randomized and the investigators were not blinded to allocation during experiments and outcome assessment. Statistical significance between conditions was assessed by two-tailed Student's t-tests. All error bars represent s.e.m., and significance between conditions is denoted as * P < 0.05; * * P < 0.01; * * * P < 0.001 and * * * * P < 0.0001. Raw data from independent replicate experiments can be found in Supplementary Table 4 . Statistical data for each quantitative experiment, including mean, s.e.m., and exact P values can be found in the Statistics Source Data (Supplementary Table 4) .
Data availability. The RNA-seq data that support the findings of this study have been deposited in the GEO database: GSE82246. Source data for all of the figures have been provided as Supplementary Table 4 . All other data supporting the findings of this study are available from the corresponding author on request.
